Human Microbiome Market Growth Drivers and Challenges:
Growth Drivers
- Growing Incidence of Respiratory Diseases – Ongoing studies state that the lung microbiome increases the proneness to respiratory diseases and influences responses to treatment. Hence, the surge in investment in comprehending the lung microbiome to develop both diagnostic and prognostic biomarkers for respiratory diseases in clinical settings will drive market growth.
- Increasing Prevalence of Gastrointestinal Disorders – According to a study, globally around 35% of people lived with functional gastrointestinal disorders in 2021. It is expected that with the growing cases of gastrointestinal disorders and digestive health, including diarrhea, constipation, and bowel incontinence, the rising influence of the human gut microbiome in both health and disease is slated to expand the market in the upcoming years.
- Rising Health Spending and Extensive Research About Human Microbiome – The increasing involvement of the human microbiome in human metabolism, nutrition, physiology, and immune function is responsible for several ongoing studies on the human microbiome and its function. The rising need to eliminate the growing healthcare expenditure worldwide by improving the gut microbiota and the human microbiome is poised to drive market expansion.
Challenges
- Strict Government Rules & Regulations- The emerging regulations by the government for the market are one of the major factors counted to slow down the market growth. For instance, probiotics are regarded as dietary supplements and no microbiome-based probiotics have received FDA approval as live biotherapeutic products (LBP).
- Lack of Knowledge about Human Microbiome Products
- Absence of Sufficient Research on the Human Microbiome
Human Microbiome Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
23.5% |
|
Base Year Market Size (2025) |
USD 1.37 billion |
|
Forecast Year Market Size (2035) |
USD 11.31 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of human microbiome is assessed at USD 1.66 billion.
The global human microbiome market size was valued at around USD 1.37 billion in 2025 and is projected to grow at a CAGR of more than 23.5%, reaching USD 11.31 billion revenue by 2035.
North America human microbiome market will hold around 35% share by 2035, driven by rising pet adoption and increasing prevalence of lifestyle diseases.
Key players in the market include Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, Inc., Second Genome Inc., Synthetic Biologics, Inc., YSOPIA Bioscience, 4D Pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc.
